FEB 27, 2017 6:05 AM PST

Study Links Immunotherapy Response To Gut Microbiome

WRITTEN BY: Xuan Pham

Immunotherapy, the technique of using the immune system to fight off disease, is one of the most promising avenues for anticancer treatments. However, even with the help of the immune system, not all immunotherapy drugs produce the same response across patients. This variability has been attributed to genetic differences between individuals. And now, a new study reports another cause for drug variability: the bacteria residing in patients’ guts.

In studying the melanoma patients’ variable response to an immunotherapy, researchers at the University of Texas MD Anderson Cancer Center identified a crucial link with the patients’ gut microbiome. Specifically, those with a more diverse microbiome showed better response to the immunotherapy, which led to better outcomes.

The immunotherapy under investigation involves PD-1 immune checkpoint inhibitors. This drug works by blocking a programmed death receptor in the body’s immune cells, allowing these cells to perk up longer and attack the tumor. But while effective, it doesn’t work for everybody. “Anti-PD1 immunotherapy is effective for many, but not all, melanoma patients and responses aren't always durable,” said Jennifer Wargo, an associate professor of Surgical Oncology, and the study’s senior author.

Wargo and her team analyzed the microbiome of 233 melanoma patients through oral swab and fecal samples. They identified a subset of patients who received anti-PD-1 therapy, and classified that group to those who responded and those who didn’t.

This revealed a striking pattern about the microbiome. In particular, Clostridiales bacteria were found in high abundance in the guts of responders. Furthermore, these people had a more diverse range of bacteria. By contrast, those who didn’t respond to immunotherapy had more uniform bacteria species, including a higher concentration of Bacteroidales bacteria.

“Our findings point to two potential impacts from additional research – analyzing the diversity and composition of the microbiome to predict response to immunotherapy and modulating the gut microbiome to enhance treatment,” said Wargo, who is also the co-leader of the Melanoma Moon Shot program.

So far, the results represent the first link between immunotherapy response and microbiome influence. However, to establish causal relationship between these two factors would require careful clinical trials, which Wargo say will begin later this year. Such studies will provide context as to which bacteria are truly beneficial, and how we can modulate these microorganisms to give patients better outcomes.

Additional sources: MD Anderson Cancer Center

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
DEC 23, 2019
Health & Medicine
DEC 23, 2019
Are Popular Gyms Promoting Indoor Tanning?
You might assume that by now, most humans are aware of the dangers of indoor tanning beds. However, many popular gyms include tanning beds as a perk of mem...
JAN 20, 2020
Genetics & Genomics
JAN 20, 2020
Epigenetic Changes Make Breast Cancer Cells Drug Resistant
Researchers have found that changes in the structure of the genome in breast cancer cells can make them resistant to drug therapies....
FEB 09, 2020
Microbiology
FEB 09, 2020
Investigating the Links Between Viruses and Cancer
The Pan-Cancer Analysis of Whole Genomes (PCAWG) has brought over 1,300 scientists together to gain new insights into the genetics of cancer....
FEB 12, 2020
Genetics & Genomics
FEB 12, 2020
Vapers Have Epigenetic Alterations Like Those Seen in Smokers
The activity of genes can be altered with chemical tags that get added to the genome, so-called epigenetic modifications....
FEB 14, 2020
Cancer
FEB 14, 2020
Cataloging Cancer: DNA fingerprints at work
New research published as part of a global Pan-Cancer Project highlights the world’s most comprehensive catalog to date of DNA fingerprints of cancer...
FEB 19, 2020
Immunology
FEB 19, 2020
Testing the Immune Response to Ovarian Cancer Treatment
There is a new diagnostic test for the deadliest form of gynecological cancer – ovarian cancer. Better tests mean better diagnostics, and better diag...
Loading Comments...